Key result
Proteomic profiling identifies 11 candidate biomarkers distinguishing resistant hypertension from standard hypertension.
Why the study?
The pathogenesis of resistant hypertension remains unclear, and proteomics may help identify diagnostic biomarkers and improve understanding and management.
What are the diagnostic serum protein biomarkers for resistant hypertension compared to standard hypertension?
Observational (n=50)
What are the diagnostic serum protein biomarkers for resistant hypertension compared to standard hypertension?
Proteomic analysis identified 11 serum proteins with diagnostic potential for resistant hypertension, offering insights into its pathogenesis.
May identify proteomic targets in resistant hypertension; leaves open clinical translation pending validation.
Background: This study delves into the intricacies of resistant hypertension (RH), a prevalent yet enigmatic chronic cardiovascular ailment that is linked to a myriad of complications. Although its full pathogenesis is still shrouded in mystery, the field of proteomics offers a beacon of hope, with its potential to shed light on the proteins that orchestrate the tapestry of life. Harnessing the power of proteomics is essential for demystifying the pathogenesis of RH, enabling more precise diagnostics and treatments, and ultimately improving prognostic outcomes. Methods: Our approach was to employ rigorous statistical analyses to home in on proteins with significant expression variances between our two cohorts. We complemented this with bioinformatics tools to unravel the intricate functions and pathways of these proteins. By synthesizing these insights with the clinical profiles of our patients, we were able to distill a set of definitive biomarkers with diagnostic potential. In our quest for clarity, we also embarked on a retrospective journey, amassing and scrutinizing clinical data from both RH and hypertension (HTN) patients. We crafted and rigorously assessed risk factor models to evaluate their diagnostic prowess. Results: Our exploration spanned across 30 blood samples from RH patients and 20 from those grappling with HTN. Our inquiry yielded some compelling revelations: (1) RH patients showcased 29 unique proteins, in contrast to the 59 unique proteins found in HTN patients. A deeper dive into the proteomic data unveiled molecular functions predominantly tied to lipid metabolism, protein networking, and oxidative stress, with a spotlight on pathways such as cholesterol metabolism, coagulation, and the complement cascade. (2) By charting receiver operating characteristic curves and rigorously analyzing the proteomic data, we surfaced 11 proteins with notable diagnostic potential, tightly interwoven with clinical metrics. Conclusion: Our research has pinpointed 11 proteins that stand as promising serum biomarkers, endowed with significant diagnostic value. This discovery marks a stride towards a more nuanced understanding and management of resistant hypertension.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2024) conducted an observational in Resistant hypertension (n=50). Resistant hypertension vs. Hypertension was evaluated on Diagnostic serum biomarkers. Proteomic profiling identified 29 unique proteins in resistant hypertension versus 59 in hypertension, yielding 11 proteins with notable diagnostic potential.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: